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Background. Myocardial inﬂammation following acute ischemic injury has been linked to poor cardiac remodeling and heart
failure. Many studies have linked myeloperoxidase (MPO), a neutrophil and inﬂammatory marker, to cardiac inﬂammation in
the setting of acute coronary syndrome (ACS). However, the prognostic role of MPO for adverse clinical outcomes in ACS
patients has not been well established. Methods. MEDLINE and Cochrane databases were searched for studies from 1975 to
March 2018 that investigated the prognostic value of serum MPO in ACS patients. Studies which have dichotomized patients
into a high MPO group and a low MPO group reported clinical outcomes accordingly and followed up patients for at least 30
days to be eligible for enrollment. Data were analyzed using random-eﬀects model. Sensitivity analyses were conducted for
quality control. Results. Our meta-analysis included 13 studies with 9090 subjects and a median follow-up of 11.4 months. High
MPO level signiﬁcantly predicted mortality (odds ratio (OR) 2.03; 95% conﬁdence interval (CI): 1.40-2.94; P < 0 001), whereas it
was not signiﬁcantly predictive of major adverse cardiac events and recurrent myocardial infarction (MI) (OR 1.28; CI: 0.921.77, P = 0 14 and OR 1.23; CI: 0.96-1.58, P = 0 101, respectively). Hypertension, diabetes mellitus, and age did not aﬀect the
prognostic value of MPO for clinical outcomes, whereas female gender and smoking status have a strong inﬂuence on the
prognostic value of MPO in terms of mortality and recurrent MI (metaregression coeﬃcient -8.616: 95% CI -14.59 to -2.633,
P = 0 0048 and 4.88: 95% CI 0.756 to 9.0133, P = 0 0204, respectively). Conclusions. Our meta-analysis suggests that high
MPO levels are associated with the risk of mortality and that MPO can be incorporated in risk stratiﬁcation models that
guide therapy of high-risk ACS patients.

1. Introduction
Cardiovascular disease is the leading cause of death worldwide [1]. Acute coronary syndrome (ACS) has the worst
prognosis among cardiovascular diseases with signiﬁcant
impact on morbidity and mortality. However, ACS patients
are a heterogonous population with variable pathologies
and clinical outcomes. Methods for risk stratiﬁcation that
incorporate biological variables such as heightened inﬂammation after cardiac injury are lacking. While troponin and
other cardiac markers have been shown to estimate the
degree of initial ischemic insult and long-term clinical events

[2], the prognostic value of markers of inﬂammation is not
well established.
Cardiomyocyte damage has been shown to initiate a systemic and local inﬂammatory response that results in worsening cardiac remodeling and long-term cardiac and clinical
adverse events [3, 4]. This response initiates the mobilization,
recruitment, and activation of neutrophils and other inﬂammatory cells. Upon activation, neutrophils degranulate and
release inﬂammatory cytokines such as myeloperoxidase
(MPO) which aids in the clearance of dead cells and tissues
but has been shown to exert atherogenic and adverse vascular
eﬀects [5, 6]. A robust body of well-designed, well-controlled
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foundational studies conducted in humans and animal
models collectively supports the premise that inﬂammation
and circulating inﬂammatory cells after myocardial infarction are detrimental for cardiac recovery [7, 8]. All these
properties make MPO a potential prognostic tool for predicting future adverse clinical outcomes in ACS patients.
Studies that have been conducted to evaluate the prognostic value of MPO in ACS patients showed discrepant
results [9, 10] and included a heterogeneous patient population, and their sample size was insuﬃcient to provide solid
conclusions. Therefore, we conducted this protocol-driven
systematic review and meta-analysis to explore the prognostic value of MPO in ACS patients. We focused on studies that
included ACS patients and stratiﬁed patients’ outcomes
based on the plasma MPO levels.

2. Materials and Methods
We conducted this protocol-driven systematic review and
meta-analysis according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) [11].
We sought to compare the 30-day prognosis of ACS patients
with high vs. low MPO levels. MEDLINE, Scopus, and
Cochrane databases were searched from inception of myeloperoxidase until March 2018. Further details about the search
strategy and terms are shown in the Supplemental Table 1.
The references of relevant papers were also screened for
potential eligible studies. The abstracts of the American
Heart Association, American College of Cardiology, and
European Society of Cardiology were screened over the last
2 years for eligible studies.
To be eligible for inclusion in our analysis, studies had
to meet the following criteria: (1) patients are divided
according to a cutoﬀ value of serum MPO into “high”
and “low,” (2) patients were followed up for at least 30
days, and (3) absolute numbers of clinical outcome events
were reported. Exclusion criteria were (1) irretrievable data,
(2) review articles and editorials, and (3) studies including
less than 50% subjects with an index diagnosis of ACS.
ACS was deﬁned as either ST segment elevation myocardial infraction (STEMI), non-STEMI, or unstable angina.
STEMI is deﬁned according to previously published criteria
[12, 13] or the WHO criteria [14]. Non-STEMI is deﬁned
as at least 10-15 minutes of chest pain at rest and elevated
biomarkers of myonecrosis, ST-segment deviation, or Twave abnormalities. Unstable angina was deﬁned as a typical chest pain at rest with new ST segment changes and
peak cardiac troponin I levels within the normal range.
Prespeciﬁed outcomes of our analyses were mortality,
major adverse cardiac events (MACE), and recurrent
myocardial infarction. Because of the variability of the
deﬁnition of the composite of MACE, we included only
studies that speciﬁcally reported MACE or used a traditional deﬁnition of its components.
2.1. Data Extraction and Critical Appraisal. Two reviewers
(A.A-L and M.A) independently screened the full text of
the retrieved studies and used a standardized form to extract
the data from each study. For each outcome, absolute event
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numbers were included and results are expressed as a ratio
of total participants with complete follow-up. Patients were
divided into 2 groups, above and below the median level of
MPO. Regarding reports that investigated the same subjects
at diﬀerent follow-up time points, we extracted data pertaining to outcomes from the longest follow-up report. We used
the Newcastle-Ottawa quality assessment scale (NOS) to
assess the quality of included studies [15].
2.2. Statistical Analyses. The prespeciﬁed outcomes of our
analyses were mortality, major adverse cardiac events
(MACE), and recurrent myocardial infarction. Summary
estimates were calculated as odds ratios (OR) with 95% conﬁdence intervals (CI) using the random-eﬀects model based
on DerSimonian and Laird’s meta-analytic statistical method
[16]. Considering that the heterogeneity of the included studies might inﬂuence the prognostic eﬀects, we prespeciﬁed the
use of the random-eﬀects model to assess eﬀect sizes. The I 2
index was used to summarize the proportion of the total variability in the estimate. The I 2 statistic is derived from the Q
statistic and describes the percentage of total variation across
studies that is due to heterogeneity; values of 25%, 50%, and
75% correspond to low, moderate, and high heterogeneity,
respectively [17] [18]. Sensitivity analyses were performed
using the one-study-removed and the cumulative analysis
methods in order to assess the inﬂuence of each study on
the overall pooled results of the meta-analysis. We used
Egger’s test and visual inspection of Funnel plots to assess
for publication bias [19].
2.3. Metaregression Analysis. Using log-transformed OR as
dependent variable, metaregression analyses were performed
to determine whether the prognostic value of MPO was modulated by prespeciﬁed study-level factors including age and
percentage of female gender, patients with index diagnosis
ACS, smoker, diabetes mellitus, and hypertension among
study populations. Metaregression was performed with unrestricted maximum-likelihood method (inverse varianceweighted regression) on the event rate log-transformed
before being used as independent variables in linear metaregression analyses [20]. The statistical level of signiﬁcance was
2-tailed P < 0 05. All statistical analyses were performed
using Comprehensive Meta-Analysis version 3.0 software
(Biostat Inc., New Jersey, USA).

3. Results
The ﬁnal analysis included 13 studies that enrolled 9090
subjects with a median follow-up of 11.4 months. The
selection process is summarized in Figure 1. Interreviewer
agreement on study eligibility was 100%. The baseline characteristics of the included patients are shown in Table 1.
Overall, patients with high MPO had similar baseline
characteristics compared to those with low MPO. The different deﬁnitions of MACE in the included studies in the
meta-analysis are shown in Supplemental Table 2. The
quality assessment of each included study is shown in
Supplemental Table 3.
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Records identified through
MEDLINE database searching
(n = 3586)

Additional records identified
through Cochrane database
(n = 462)

Records after duplicates removed
(n = 4048)

Records excluded after title
and abstract screening
(n = 4021)

Full-text articles assessed
for eligibility
(n = 27)

Studies included in
qualitative synthesis
(n = 13)

Full-text articles excluded,
with reasons
(n = 14)
(i) >50% of their subjects
don’t have ACS (n = 8)
(ii) Unavailable absolute
number of events
according to MPO
grouping (n = 30)
(iii) Follow up less than 30
days (n = 2)
(iv) Outcomes of our interest
are not reported (n = 1)

Figure 1: Flow chart of search strategy.

The primary endpoint, all-cause mortality, was signiﬁcantly higher in patients with high MPO compared to
those with low MPO (OR 2.03; CI: 1.40-2.94, P < 0 001)
(Figure 2). The incidence of MACE and recurrent myocardial infraction trended higher among patients with high
MPO (OR 1.28; CI: 0.92-1.77, P = 0 14 and OR 1.23; CI:
0.96-1.58, P = 0 101, respectively) (Figures 3 and 4). The
heterogeneity in our analyses was moderate based on the
I 2 statistic of 17%, 48%, and 77% for recurrent MI, mortality, and MACE, respectively.
Metaregression analysis of the primary endpoints stratiﬁed by baseline characteristics, such as age, prevalence of
hypertension, percentage of ACS in the study population,
and diabetes mellitus, showed no signiﬁcant interactions
(Supplemental Figures 1-3). However, there was a
signiﬁcant inverse correlation between female gender and
the prognostic value of MPO for both mortality (correlation
coeﬃcient -4.23, 95% CI: -7.88 to -0.59, P = 0 02) and
recurrent MI (correlation coeﬃcient -2.37, 95% CI: -4.69 to
-0.03, P = 0 047) (Supplemental Figures 1 and 3). On the
other hand, smoking showed a signiﬁcant direct correlation
with the OR of recurrent MI; hence, the prognostic value of
high MPO on recurrent MI was greater among smokers
than nonsmokers (correlation coeﬃcient 5.21, 95% CI: 1.08
to 9.34, P = 0 01) (Supplemental Figure 3).

3.1. Sensitivity Analyses. Sensitivity analyses using the “onestudy-removed” method did not show signiﬁcant changes
in the summary odds ratio estimates for any outcome
assessed (Supplemental Figure 4). Cumulative meta-analysis
showed a relatively stable accumulation of evidence for
primary endpoints assessed (Supplemental Figure 5). We
also stratiﬁed the studies based on sample collection
method. The results were inconclusive for the sample
collection tube because there was a signiﬁcant imbalance
with higher number of studies that utilized EDTA
collection tube compared to those using heparin or citrate
collection tubes, thus precluding a deﬁnitive conclusion
regarding the impact of sample collection method on the
prognostic value of MPO in our analysis.
We also stratiﬁed the studies based on sample collection
timing. There was heterogeneity in the sample collection
time in relation to the onset of chest pain as detailed in
Table 2. There was no correlation between the timing of
blood collection and the prognostic value of MPO in mortality (-0.00, 95% CI: -0.02 to 0.02, P = 0 99), MACE (-0.02,
95% CI: -0.15 to 0.11, P = 0 78), or recurrent MI (-0.00,
95% CI: -0.03 to 0.03, P = 0 99).
3.2. Publication Bias. No clear evidence of publication bias
was observed on visual inspection of the Funnel plots
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Table 1: Patients’ characteristics of the studies included in the meta-analysis.
STEMI NSTEMI UAP
(%)
(%)
(%)
≥50% of patients
have cTnI ≥ 0 09

Apple et al.∗ [31]
Baldus et al. [34]

0

Brugger-Andersen
et al. [30]
Cavusoglu et al. [38]

0
AMI 100

12

43

NA
100
0
45

Chang et al. [28]

AMI 53.9

NA

Eggers et al. [9]

AMI 36.6

21.8

Kaya et al. [10]

100

0

0

Koch et al.§ [26]

43

NA

NA

MPO cutoﬀ
value

Sample
size

Age

Female Smoking Diabetes Hypertension
(%)
(%)
(%)
(%)

≤125.6 mcg/L
>125.6 mcg/L

172
285

57 ± 16

43

NR

<350 μg/L

376

61 4 ± 10 5

28.7

≥350 μg/L

171

62 5 ± 10 4

31

≤26.8 mcg/L
>26.8 mcg/L

142
141

64 ± 13

20.8

≤20.34 ng/mL

91

65 ± 9 3

0.0

32

59

84

>20.34 ng/mL

91

64 7 ± 10 8

0.0

43

34

83

<1150 ng/mL

95

59 9 ± 12 8

10.55

34.7

33.7

60

≥1150 ng/mL

33

64 3 ± 12 1

15.1

39.4

51.5

57.6

≤208.1 pmol/L
>208.1 pmol/L

235
61

66 (55, 76)

33.9

17.2

16.2

37.3

≤68 ng/mL

37

56 ± 11

26

61

20

37

>68 ng/mL

36

57 ± 13

21

66

32

55

≤306.3 pmol/L

396

63 7 ± 13 0

30.3

32.9

19.2

70.9

>306.3 pmol/L

267

65 ± 12

31.1

33

23.6

67.8

762
762

61 (52, 69)
61 (53, 70)

32.1
34

28.7
29.5

25.1
28.9

67.2
63.9

24.9

57.9

42.5

8.2

35.4

40

12.5

36.9

38.9

10.4

24.4

Morrow et al. [39]

0

35

65

≤884 pg/mL
>884 pg/mL

Mocatta et al. [27]

81.1

18.9

0

≤55 ng/mL
>55 ng/mL

242
243

61 7 ± 11 0

19.9

NA

12.7

NR

Oemrawsingh†
et al. [40]

0

0

100

<350 μg/L
≥350 μg/L

376
171

62 (54, 69)

20

40

14

42

Rahman et al. [32]

65

30

5

<285.5 pmol/L
≥285.5 pmol/L

30
70

NR

20

NR

NR

NR

Scirica et al. [29]

0

48.3

49.2

≤670 pg/mL
>670 pg/mL

2507
1845

64

35.1

25

32.3

74.6

STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; UAP: unstable angina; MPO: myeloperoxidase; CTn1: cardiac
troponin I; AMI: acute myocardial infraction; NA: not available. Continuous variables are presented in either median or mean ± SD. Categorical variables are
presented in percentages. ∗ Apple et al. reported that the median cardiac troponin of the whole cohort is 0.09 μg/L. †Oemrawsingh et al. is a longer follow-up
report of Baldus et al.’s study subjects. §Reported that ACS-negative patients are 10.8% of the study population.

Study name

Statistic for each study

Events/total

Odds
ratio

Lower
limit

Upper
limit

Z value

P value

High
MPO

Low
MPO

Apple 2007
0.900
Baldus 2003
1.263
Chang 2009
14.880
Eggers 2009
2.633
Kaya 2012
5.806
Koch 2014
2.695
Mocatta 2007 2.363
Rahman 2016 0.848
Scirica 2011
1.621
Overall
2.031

0.395
0.365
2.971
1.207
0.643
1.367
1.412
0.147
1.215
1.403

2.051
4.372
74.529
5.743
52.408
5.311
3.956
4.902
2.162
2.939

−2.051
0.368
3.285
2.432
1.567
2.864
3.272
−0.184
3.283
3.756

0.802
0.713
0.001
0.015
0.117
0.004
0.001
0.854
0.001
0.000

15 / 285
4 / 171
8 / 33
12 / 61
5 / 36
24 / 267
52 / 243
4 / 70
105 / 1845

10 / 172
7 / 376
2 / 95
20 / 235
1 / 37
14 / 396
25 / 242
2 / 30
90 / 2507

Relative
weight

Odds ratio and 95% Cl

11.88
6.78
4.46
12.65
2.57
14.66
18.53
3.85
24.62
0.1

0.2

0.5

1

2

5

10

Figure 2: Forest plot for all-cause mortality. High myeloperoxidase level was associated with signiﬁcantly higher risk of mortality (odds ratio
2.03; 95% conﬁdence interval (CI): 1.403-2.939; P < 0 001).
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Statistic for each study

Study name

Apple 2007
Brügger-Andersen 2008
Chang 2009
Eggers 2009
Kaya 2012
Oemrawsingh 2011
Overall

Events/total

Odds
ratio

Lower
limit

Upper
limit

Z value

P value

High
MPO

Low
MPO

1.895
0.674
1.003
1.497
4.125
1.500
1.278

0.869
0.361
1.001
0.752
1.184
1.086
0.921

4.132
1.257
1.005
2.981
14.366
2.073
1.773

1.608
−1.240
2.944
1.148
2.226
2.458
1.469

0.108
0.215
0.003
0.251
0.026
0.014
0.142

27 / 285
16 / 75

9 / 172
64 / 223

14 / 61
12 / 36

39 / 235
4 / 37

Relative
weight

Odds ratio and 95% Cl

11.28
14.65
31.32
13.12
5.64
23.99
0.1

0.2

0.5

1

2

5

10

Figure 3: Forest plot for major adverse cardiac events (MACE). High myeloperoxidase showed a trend towards higher risk of MACE
(odds ratio 1.27; CI: 0.92-1.77, P = 0 14).

Study name

Cavusoglu 2007
Eggers 2009
Kaya 2012
Koch 2014
Marrow 2008
Scirica 2011
Overall

Statistic for each study

Events/total

Odds
ratio

Lower
limit

Upper Z value P value
limit

2.319
0.806
5.435
2.500
1.280
1.050
1.231

1.050
0.318
0.252
0.592
0.965
0.841
0.960

5.120
2.081
2.045 −0.453
117.236 1.080
10.550 1.247
1.696
1.715
1.311
0.430
1.578
1.641

0.037
0.651
0.280
0.212
0.086
0.667
0.101

High
MPO

Relative
weight

Odds ratio and 95% Cl

Low
MPO

8.62
6.47
0.65
2.85
36.71
44.70

22 / 91
11 / 91
6 / 61
28/ 235
2 / 36
0 / 37
5 / 267
3 / 396
127 / 762 103 / 762

0.1

0.2

0.5

1

2

5

10

Figure 4: Forest plot for recurrent myocardial infraction (MI). High myeloperoxidase showed a trend towards higher risk of recurrent MI
(odds ratio 1.23; CI: 0.96-1.57, P = 0 101).

(Supplemental Figures 6-8). Our Egger’s regression test
did not show signiﬁcant risk of publication bias
(P = 0 39 for all-cause mortality, 0.06 for MACE, and 0.2
for recurrent MI).

4. Discussion
Risk stratiﬁcation for patients with ACS is an evolving ﬁeld,
and the prognostic role of inﬂammatory markers such as
MPO has not been fully investigated. In this comprehensive
systematic review and meta-analysis, we conﬁrm the strong
correlation between elevated plasma MPO levels and cardiac
outcomes, including mortality, among patients with acute
coronary syndrome. More importantly, our results were consistent across multiple study designs and patient characteristics. These results support a potential role for MPO as part of
multimarker risk stratiﬁcation model to guide future individualized therapies to the highest risk population. Future prospective studies examining the prognostic value of MPO in
comparison of other biomarkers of inﬂammation such as
high-sensitivity C-reactive protein (hs-CRP) are warranted.
Myocardial injury triggers a series of signaling events to
communicate with the bone marrow and peripheral blood
cells (PBCs) through processes that are just now being elucidated. After myocardial infarction, circulating inﬂammatory
cells such as neutrophils are a poor prognostic indicator, in
part because of their contribution to infarct expansion and

impaired cardiac remodeling, thereby promoting the progression to adverse remodeling and heart failure [21, 22].
Indeed, this initial injury response may actually confer
long-term harm because reduction in the initial recruitment
of inﬂammatory cells can reduce infarct size and prevent
cardiac remodeling following cardiac injury [23]. In addition
to eﬀects on the myocardium, circulating inﬂammatory cells
following ACS accelerate experimental atherosclerosis in
animal models thus initiating a vicious cycle; thus, this type
of cycle may contribute to recurrent coronary events in
humans [24]. Therefore, identifying markers of inﬂammation and inﬂammatory cell activity can help risk stratify
ACS patients and guide future therapies. MPO is a product
of inﬂammatory neutrophils during their degranulation
and can aid in the process of clearing dead cells. However,
MPO has been linked to atherosclerosis and recurrent coronary events. MPO enhances LDL cholesterol oxidation,
hence destabilizes coronary atherosclerotic plaque [25].
Additionally, MPO limits endothelial-derived nitric oxide
bioavailability which impairs coronary vessel dilatation and
worsens cardiac ischemia [6].
Myeloperoxidase as a prognostic marker in ACS patients
has generated conﬂicting results in clinical studies. The
majority of clinical data has conﬁrmed the prognostic value
of MPO in predicting mortality [9, 26–29], and our analysis
conﬁrmed this correlation to be highly signiﬁcant. However,
although there was strong correlation between MPO levels

Morrow et al.
[39]

∗

Oemrawsingh et al. is a longer follow-up report of Baldus et al.’s study; the study’s subjects received heparin before blood samples were withdrawn.

Sample
collection
method

CitrateEDTAHeparinCitrateEDTAEDTAcontaining
NR
anticoagulated
NR
NR
anticoagulated
NR
anticoagulated anticoagulated anticoagulated
tubes
tubes
tubes
tubes
tubes
tubes
Within 6
Within 3.1 Within 8.7
After 26.1
From 24 to 96
Within 4-6
≥12 hours
After 0.8 hour hours of
At
hours from hours from
Time of
hours from
hours after
days from the
after
NR
hospital from hospital the onset
the onset
the onset
sample
hospital
hospital
onset of
hospital
of
admission
admission
of
of
collection
admission
admission
symptoms
admission
symptoms
symptoms symptoms

BruggerCavusoglu
Chang
Kaya et al.
Mocatta et al.
Apple et al.
Baldus
Andersen et al.
Eggers et al. [9]
Koch et al. [26]
∗
et al. [38] et al. [28]
[10]
[27]
[31]
et al. [34]
[30]

EDTAanticoagulated
tubes

NR

NR

Scirica et al.
[29]
NR

Rahman
et al.
[32]

Table 2: Sample collection methods and time of sample collection in relation to onset of chest pain/hospital admission of the included studies.

6
Mediators of Inﬂammation

Mediators of Inﬂammation
and other clinical events such as MACE and recurrent myocardial infarction, this association did not reach statistical
signiﬁcance in individual trials or our analysis [9, 30, 31].
There are multiple factors that can explain the lack of this
correlation. Some of the studies were underpowered to reach
a valid conclusion especially in individual endpoints [10, 30,
32]. Other studies enrolled a heterogeneous population of
patients with chest pain (mixture of ACS and non-ACS).
Indeed, it has been shown that MPO levels correlate with
the severity of ACS pathology [33]. In accordance with these
ﬁndings, we found that the prognostic value of MPO was the
highest among studies with high proportion of AMI patients
[10, 27] compared to those with higher percentage of unstable angina subjects [29, 34]. Additionally, timing of sample
collection could have played a role in the variable results
since MPO level was signiﬁcantly higher immediately after
STEMI [26, 35]. Although studies adopted diﬀerent MPO
cutoﬀ values, our analysis was primarily focused on the prognostic value of MPO rather than its absolute value since the
included studies used diﬀerent MPO assays. Therefore,
despite the fact that MPO cutoﬀ value was not the same,
stratifying patients based on a certain MPO cutoﬀ provided
valuable prognostic information in patients with acute coronary syndrome.
We performed additional sensitivity analyses attempting
to unify the included studies based on methodology and sample collection. When we focused our analyses on studies that
reported using similar methodology, we observed consistent
prognostic value of MPO for all endpoints examined. Similarly, we did not see signiﬁcant interaction between most of
the baseline characteristics or time of sample collection and
the prognostic value of plasma MPO. Additionally, the predictive value of MPO for all-cause mortality and MACE
was consistent in the “one-study-removed” and cumulative
analyses suggesting the generalizability of our ﬁndings.
There are limitations to our analysis inherent in conducting a meta-analysis using published patient data and the
methodological diﬀerences among the included studies.
Included studies enrolled heterogeneous patient populations
and adopted diﬀerent deﬁnition of clinical outcomes which
could have inﬂuenced the results of the pooled analyses.
While we attempted to address this limitation by using comprehensive sensitivity and metaregression analyses, we could
have failed to include other clinical parameters that were
not reported in the published manuscripts. Furthermore,
the sample withdrawal timing was diﬀerent across the
included studies which could have inﬂuenced the results;
however, there was no signiﬁcant correlation between the
time of sample withdrawal and the prognostic value of
MPO for any of the outcomes. Finally, statin therapy, which
is known to downregulate MPO expression [36], was not
reported in most of the included studies, and therefore, we
could not conduct sensitivity analysis based on the proportion of patients receiving statin.
This meta-analysis attempted to focus on a homogeneous
population of studies with high percentage of ACS patients,
thus addressing some of the variability in the literature.
Our results have signiﬁcant implications in clinical practice.
Integrating MPO in risk stratiﬁcation models could have an
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additional value in identifying patients at higher risk of
developing heart failure, recurrent ischemia, and clinical
events specially mortality. The predictive value of MPO is
more speciﬁc in patients with STEMI and high-risk
NSTEMI where the damage is higher and more inﬂammatory cells are more activated [28, 37].

5. Conclusions
MPO is a powerful prognostic marker for clinical outcomes
in patients with acute coronary syndrome. Our results advocate for more comprehensive risk assessment tools that
incorporate MPO to more personalized medical and invasive
management for patients with ACS. Further studies examining management strategies based on peak MPO level are
needed to assess the clinical utility of this novel biomarker.
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